Abstract:However, increasing research has revealed that the impact of COVID-19 on children is particularly noteworthy, as they were initially thought to be less susceptible to severe outcomes compared to adults. It has been observed that pulmonary involvement in children can be more severe than in adults, and numerous case reports have highlighted the occurrence of multisystem involvement. Clinical treatment and management approaches for pediatric patients cannot solely rely on data derived from adult cases 2 . This editorial aimed to synthesize the latest research findings to explore the impact of COVID-19 on children, including conditions such as acute necrotizing encephalopathy (ANE), aseptic meningoencephalitis (ME), febrile seizures (FSs), and multisystem inflammatory syndrome in children (MIS-C). These findings underscore the need for heightened awareness among healthcare providers.As the COVID-19 pandemic has progressed, different SARS-CoV-2 variants have led to varying clinical presentations. Initially, children infected with SARS-CoV-2 exhibited mild respiratory symptoms. However, in later stages of the pandemic, particularly in patients infected with the Delta and Omicron variants, more life-threatening nonrespiratory complications have emerged 3,4 . When clinical symptoms closely resemble other diseases, it can be challenging to make an accurate diagnosis promptly.Multisystem inflammatory syndrome in children (MIS-C) is a systemic inflammatory syndrome that may occur in children following infection with SARS-CoV-2. The early clinical presentation of MIS-C is quite similar to Kawasaki disease, often presenting with symptoms such as fever, conjunctival injection, and rash 5 . MIS-C has been reported mainly in Western countries; however, the incidence of MIS-C appears to be lower in Asian regions 6 . According to a previous study, among 137 patients with MIS-C, only 4 (2.5%) exhibited symptoms of posterior pharyngeal swelling. If such cases occur in Asian regions where the incidence of MIS-C is lower and the incidence of Kawasaki disease is higher, clinicians should assess the risk of MIS-C in their patients 7 . Both conditions can cause inflammation in multiple organ systems, requiring different management approaches. Therefore, it is crucial for clinicians to accurately diagnose and differentiate these conditions, especially when rare clinical symptoms, such as retropharyngeal edema, are present.A few case reports have noted that patients with MIS-C may present with retropharyngeal edema. For example, a case report from Japan (Takanori Suzuki et al., 2023) described a previously healthy nine-year-old boy who developed severe retropharyngeal edema resistant to intensive antibiotic treatment. Enhanced CT imaging revealed typical findings of the disease. Throat swabs and blood cultures performed during the initial examination were negative; however, records indicated a COVID-19 infection three weeks prior to the onset of symptoms. The patient, aged nine, which is a common age for MIS-C onset, experienced rapid symptom resolution and normalization of laboratory data following intravenous immunoglobulin treatment.This case, along with previous reports 7 , suggests that early use of intravenous immunoglobulin may help prevent the progression of MIS-C and the occurrence of circulatory failure. Additionally, retropharyngeal edema might be used as a predictor for MIS-C. For febrile children with severe neck symptoms and retropharyngeal edema, if MIS-C is suspected, recent COVID-19 history should be assessed, and early intervention may prevent disease progression.According to the research conducted by Dr. Liliane N. Byamungu and colleagues (Byamungu et al., 2023), the occurrence of cytokine storms indicates immune dysregulation. If not promptly addressed, this condition can lead to significant morbidity and mortality, particularly in regions with limited medical resources and among children with human immunodeficiency virus (HIV) infection, such as in Africa.Previous studies have shown that the incidence and mortality rates of COVID-19 among hospitalized children and adolescents in these areas are significantly higher than in non African regions 9 . These risks are associated with being under 1 year of age and with selected non communicable comorbidities, such as chronic kidney disease, chronic lung disease, blood disorders, liver disease, and chronic neurological conditions.Moreover, children living in regions with high HIV prevalence or those exposed to HIV face a higher risk of severe COVID-19. This underscores the severity of COVID-19 among children with underlying medical conditions. Additionally, the results indicate that children with a history of comorbid conditions face a higher risk of severe disease and mortality, with HIV exposure and younger age being significant predictors.The impact of COVID-19 on healthcare support systems is substantial, particularly -Abstract Truncated-

Description of a national, multi‐center registry of patients with sickle cell disease and SARS‐CoV‐2 infection: Data from the Pediatric COVID‐19 United States Registry

Differences In Clinical Features And Laboratory Results Between Adults And Children With Sars-Cov-2 Infection

Children with sickle cell disease: are they protected from serious COVID-19?

Characteristics and Outcomes of Children With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Admitted to a Quaternary Hospital: A Single-Center Experience

Characteristics, Outcomes, and Severity Risk Factors Associated With SARS-CoV-2 Infection Among Children in the US National COVID Cohort Collaborative

Impact of COVID-19 on incidence, clinical presentation, and prognosis of acute chest syndrome in patients with sickle cell disease

Efficacy of Inactivated SARS-CoV-2 Vaccination in Pediatric Hematology/oncology Patients: a Real-World Study

Multisystem inflammatory syndrome in children and SARS-CoV-2: A scoping review

SARS-CoV-2 With Concurrent Respiratory Viral Infection as a Risk Factor for a Higher Level of Care in Hospitalized Pediatric Patients

Attitudes, Beliefs, and Intention to Receive a COVID-19 Vaccine for Pediatric Patients With Sickle Cell Disease

Cardiac Abnormalities Seen in Pediatric Patients During the SARS-CoV2 Pandemic: An International Experience

Thrombosis and hemorrhage experienced by hospitalized children with SARS‐CoV‐2 infection or MIS‐C: Results of the PICNIC registry

Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection

Characteristics of children admitted to hospital with acute SARS-CoV-2 infection in Canada in 2020

SARS-CoV-2 infection in children: A 24 months experience with focus on risk factors in a pediatric tertiary care hospital in Milan, Italy

Severity of SARS-CoV-2 infection in children with inborn errors of immunity (primary immunodeficiencies): a systematic review

Editorial: Ethnic differences in children in the clinical manifestation of infection with SARS-Cov-2 and its variants

Resource use and disease severity of children hospitalized for COVID-19 versus multisystem inflammatory syndrome in children (MIS-C) in Canada

COVID-19 Vaccination Status and Disease Burden in Patients with Sickle Cell Disease

Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach

Clinical and Laboratory Profile, Management and Outcome of Pediatric SARS-CoV-2 Infection Admitted at the Philippine General Hospital